Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Biomea Fusion, Inc. (BMEA)

Biomea Fusion says topline results for BMF-650 Phase I trial now expected October 2026

Neutral Impact 2 of 5 other Written later

Biomea Fusion updated the expected timing of topline results from its ongoing Phase I GLP-131 trial of BMF-650 in obese, otherwise healthy volunteers, now expected in October 2026. The filing does not disclose any trial data, and the change is a timing update only.

Key points

  • Topline results from the Phase I GLP-131 trial of BMF-650 are now expected in October 2026.
  • The trial enrolls obese, otherwise healthy volunteers.
  • The update was announced on September 22, 2026, in a Form 8-K filed under Item 8.01 Other Events.

The filing

CompanyBiomea Fusion, Inc. (BMEA)
Form8-K, current report
Filed with the SECSep 22, 2026, 4:01 PM ET
Accession number0001193125-26-397870

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.